Expression Profiling of Circulating Tumor Cells: a Prognostic and Predictive Biomarker in Cancer.
Poster Dec 01, 2014
Mikael Kubista, Robert Sjöback,Marie Jindrichova, Eva Rohlova, Vendula Novosadová, Siegfrid Hauch, Bahriye Aktas, Mitra Tewes,Maren Bredemeier, and SabineKasimir-Bauer
We have developed a strategy to predict response to treatment of cancer patients based on expression profiling of circulating tumour cells (CTCs). CTCs are collected from blood using AdnaGen immunomagnetic capture followed by expression profiling with TATAA Biocenter GrandPerformance assays via preamplification. Preliminary results from a pilot study on breast cancer (BC) patients demonstrates excellent sensitivity, technical reproducibility and identifies a set of genes that separates a group of non-responders. The approach shows great promise as liquid biopsy for the motoring of treatments and prediction of responses.
The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that regulate the expression of phase I (cytochrome P450s), phase II metabolizing enzymes and transporter genes in response to xenobiotics, including prescription drugs.READ MORE